ranibizumab

Home
Ligands
ranibizumab

GtoPdb Ligand ID: 6779

Synonyms: Fab-12 variant Y0317 | Lucentis® | muMAb VEGF A.4.6.1 | rhuFab V2

ranibizumab is an approved drug (FDA (2006), EMA (2007))

Comment: Ranibizumab is a Fab fragment of a monoclonal antibody designed to target vascular endothelial growth factor A (VEGFA).
Annotated peptide sequences for this antibody derivative are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals that ranibizumab sequences are claimed in patent WO1998045331 (clone Y0317) [2], with an expected affinity similar to clone Y0313-1. It is the Fab fragment of bevacizumab.

Biosimilars:

Name(s)	Trade name	Company	Clinical Phase	Indications
	Razumab®	Intas Pharmaceuticals	Approved (India 2015)	As per reference agent
SB11; ranibizumab-nuna	Byooviz®	Samsung Bioepis	Approved (EMA & FDA 2021)	As per reference agent
	Susvimo®	Genentech/Roche	Approved (FDA 2021)	wet AMD
FYB201; ranibizumab-eqrn	Cimerli®	Coherus BioSciences	Approved (FDA 2022)	As per reference agent
	Ranivisio®	Midas Pharma	Approved (EMA 2022)	wet AMD
	Ximluci®	STADA Arzneimittel	Approved (EMA 2022)	As per reference agent
ranibizumab biosimilar	Rimmyrah®	Qilu Pharma	Approved (EMA 2024)	As per reference agent

No information available.

No information available.

Summary of Clinical Use
Used to treat macular edema after retinal vein occlusion, age-related (wet) macular degeneration, and diabetic macular edema. Administered by intravitreal injection. In February 2015, the US FDA expanded approval to include treatment of diabetic retinopathy. FDA approval was further expaned to include myopic choroidal neovascularization (mCNV; a complication of severe near-sightedness that can lead to blindness) in January 2017.

Summary of Clinical Use

Used to treat macular edema after retinal vein occlusion, age-related (wet) macular degeneration, and diabetic macular edema. Administered by intravitreal injection.
In February 2015, the US FDA expanded approval to include treatment of diabetic retinopathy. FDA approval was further expaned to include myopic choroidal neovascularization (mCNV; a complication of severe near-sightedness that can lead to blindness) in January 2017.

Mechanism Of Action and Pharmacodynamic Effects
Binds to and inhibits the biologic activity (neo-vascularisation/vessel permeabiity) of active forms of human vascular endothelial growth factor A [3].

Mechanism Of Action and Pharmacodynamic Effects

Binds to and inhibits the biologic activity (neo-vascularisation/vessel permeabiity) of active forms of human vascular endothelial growth factor A [3].

External links
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA)

External links

For extended ADME data see the following:

Electronic Medicines Compendium (eMC)
Drugs.com
European Medicines Agency (EMA)